The Qrono-IRR collaboration will further the development of available medical countermeasures for acute radiation syndrome
PITTSBURGH (PRWEB) August 9, 2016 – Qrono Inc., a specialty pharmaceutical company focused on long-acting injectables (LAIs), and Inflammatory Response Research Inc. (IRR), a drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions, today announced a development collaboration to develop LAI medications to treat Acute Radiation Syndrome (ARS).
Sometimes known as radiation toxicity or radiation sickness, ARS is a collection of health effects caused by exposure to a high dose of ionizing radiation in a short period of time (usually minutes). Despite decades of research, there is currently a shortage of non-toxic, safe and effective medical countermeasures for radiological and nuclear emergencies. To date, the U.S. Food and Drug Administration (FDA) has approved only two treatments for acute radiation injury. This dearth of FDA approved radiation countermeasures illustrates the need for a new generation of radiation countermeasures.
World events over the past decade have highlighted the threat of nuclear incidents due to detonation of nuclear weapons by terrorists, sabotage of nuclear facilities, dispersal and exposure to radioactive materials, and accidents. Nuclear and radiological mass-casualty incidents are a significant risk, and there is a clear and urgent need to develop radiation countermeasures for military personnel, first responders, and civilian populations.
“Current therapy for acute radiation syndrome is primarily supportive,” said Dr. B. Chandler May, CEO of IRR. “In contrast, a 7-day long-acting injectable will allow exposed individuals to tolerate higher doses of radiation while protecting vital organs. This addition to treatment protocols has the potential to benefit millions of people worldwide.”
“We are thrilled to enter this partnership with Inflammatory Response Research to develop effective medical countermeasures for ARS,” commented Larry Zana, CEO of Qrono. “The potential to create a life- saving therapy for victims of nuclear / radiation incidents represents an exciting new opportunity for the QronoMetrics™ platform to expand our mission and better the lives of patients.”
Qrono reformulates FDA approved drug products and creates new, long-acting injectable (LAI) medications with improved clinical and economic benefits. Qrono’s product pipeline focuses on therapeutic areas where LAIs offer high therapeutic and economic value, such as addressing high non- adherence or solving specific drug delivery challenges. The company uses its computational drug delivery technology, called QronoMetrics™, to design LAIs significantly faster than legacy practice and with reduced clinical and technical risk. Qrono media contact: Larry Zana, CEO Phone: +1.412.213.8788 Email: email@example.com
IRR is a drug development company focused on pharmaceutical products for the treatment of inflammatory disorders and conditions, including influenza, the common cold, traumatic brain injury, and acute radiation syndrome. Their initial product is a combination of levocetirizine (Xyzal®) and montelukast (Singulair®) at specific dosing for the treatment of the common cold (behind the counter dose pack). Parallel research is focused on the development of long acting injectables for use in traumatic brain injury and acute radiation syndrome.
Patents have formally issued in the US, Australia, Mexico, Canada, and Japan for the treatment of influenza and the common cold. Intellectual Property includes seven patents pending worldwide for multiple indications. Further information is available on the Company’s website, http://www.irrinc.net. IRR media contact: B. Chandler May, CEO Phone: +1.805.403.2320 Email: firstname.lastname@example.org